HbA1c and FIB-4 as serologic markers for the risk of progression of stage A heart failure

William Grigg¹, Faisal Mahfooz², Dharmista Chaudhary¹, Isain Zapata², Douglas Duffee¹,²,³*

ABSTRACT
The use of glycosylated hemoglobin as a diabetic glycemic control and cardiovascular risk marker is well documented. It has also been suggested as a marker for early diastolic hemodynamic changes leading to clinical heart failure, but is less well characterized. This study explored the association between elevated glycosylated hemoglobin and liver Fibrosis-4 values and worsening measures of diastolic cardiac function in order to assess their potential as early serologic markers in cardiovascular disease prevention.

A retrospective cohort analysis was conducted in 102 patients presenting to the Parkview Medical Center health system who had received a full resting echo characterized by normal systolic ejection fraction and clinical risk factors associated with stage A heart failure in conjunction with glycosylated hemoglobin and Fibrosis-4 scores within a 3-month time window. Using regression analysis, measures of diastolic cardiac function were assessed in conjunction with rising glycosylated hemoglobin levels characterized as >6.5 and ≥6.5 and Fibrosis-4 scores after controlling for the presence of hypertension, coronary artery disease and valvular heart disease. Glycosylated hemoglobin levels >6.5 were significantly associated with a higher E/e’ ratio and closely associated with an elevated left atrial volume index both indicative of elevated left atrial pressure as a sensitive marker for diastolic cardiac dysfunction. Fibrosis-4 scores did not appear to be clinically associated with progression of diastolic dysfunction.

Thus, glycosylated hemoglobin may act as an early marker for identifying patients at increased risk for the progression of stage A heart failure. Fibrosis-4 scores do not appear to be related.
INTRODUCTION

The classic association of glycemic control, as represented by glycosylated hemoglobin (glyco Hb or glyco%), with progression or improvement of microvascular and macrovascular clinical complications, is well documented. Additionally, while the association of glyco Hb elevation with an advanced clinical cardiovascular syndrome described as diabetic cardiomyopathy (beyond the classic cardiac risk factors associated with diabetes mellitus) has also been well documented, the use of advanced glycation end products (AGE) as both a marker of, and treatment target for the early diastolic hemodynamic changes of diabetic cardiomyopathy, has been suggested but is less well characterized.

People with Stage A heart failure have normal cardiac structure and function but also have predisposing risks for cardiovascular disease which may not yet have manifested as symptoms of heart failure. Estimates suggest that Stage A heart failure may comprise greater than 50% of a community’s patient population and patients are commonly seen in primary care, endocrinology, cardiology and other clinics.

In light of cardio metabolic agents such as SGLT2 inhibitors which show promise in cardiovascular disease primary prevention, stage A heart failure patients may be an important target for a new therapeutic mechanism to deploy widely in preventative cardiovascular care. Showing an association between a commonly used metabolic marker and progressive hemodynamic cardiac disease would provide support for initiating medication therapy–classically prescribed in the diabetic context–to earlier use in the cardiac context, with or without a concomitant indication for hypoglycemic therapy.

Our study examined whether glyco Hb could be isolated as a hemodynamic marker of diastolic cardiac dysfunction in diabetics with stage A heart failure, who may or may not yet need initiation or titration of hypoglycemic therapy. Secondarily, a non-invasive easily obtainable marker for liver fibrosis (FIB-4; a scoring system that uses a combination of patient age, platelet count, AST and ALT.) was also assessed for its correlation to diastolic function and potential utility as a treatment marker.

METHODS

Participant inclusion and exclusion criteria

A community-based population cohort registry of all patients was identified by retrospective chart review of patients who had presented to Parkview Medical Center’s in-patient and outpatient services in Pueblo County Colorado from January 2019 to June 2020 and who had obtained a full resting echocardiogram characterized by normal LV systolic function in conjunction with glyco Hb, brain natriuretic peptide (BNP), CBC and CMP within a concomitant 3-month time frame. 2263 patients were identified. A sample of 102 participants was randomly selected for this study. All the study participants’ procedures and related parameters were part of a previously ordered medically indicated clinical evaluation. The selected sample size was determined by power analysis for detection of a 5% change in left atrial volume (LAV) examining the registry from most- to less-recent index encounter to a p value of less than 0.05 until the N value was met.

We also included a measure of liver fibrosis—as estimated by the FIB-4 equation—to assess for an association between a non-invasive marker for liver fibrosis and the same measures of diastolic cardiac function and as a measure of the glycemic status of study groups at a cutoff level of 6.5, to include those with mild diabetes who may not yet require hypoglycemic therapy, according to current guidelines.
Patient’s age, gender (M=male, F=female), body mass index (BMI), body surface area (BSA), brain natriuretic peptide (BNP), previous history of hypertension (HTN), cardiac valvular disease and coronary artery disease (CAD) were also recorded. All data was compiled from retrospective medical records for the participants selected for the sample. This study was sanctioned and approved by the Parkview Medical Center Institutional Review Board.

Echocardiography
Transthoracic echocardiography was performed in accordance with published standards and interpreted by a board-certified cardiologist independent of any knowledge of this study. The presence of hypertension was defined as greater than 140/90 measured closest in time to the index echocardiogram. Valvular disease was defined as any regurgitation or stenosis noted to be greater than mild. Coronary artery disease was defined as any of the following: any regional wall motion abnormality on echo and/or cardiac catheterization showing at least one vessel with 50% or more stenosis. All labs were processed through Parkview's central laboratory.

Statistical analysis
Means, standard deviation and range were calculated for continuous variables while frequencies and proportional percentages were calculated for categorical variables. All descriptive statistics were calculated using PROC MEANS and PROC FREQ from SAS/STAT v.9.4 (SAS Institute, Cary NC). Generalized additive models (GAMs) were used to evaluate the association of the dependent variables glycemic percentage (Glyco Hb) and liver fibrosis (FIB-4) to the independent variables of HTN, valvular disease, CAD, age, BMI, BNP, LAVI and E/e’.

Effects were introduced into a semiparametric model by including the effects of gender, HTN, valve disease and CAD as parametric independent variables (categorical variables) and age, BMI, BNP, LAVI and E/e’ as smoothing splines with 3 degrees of freedom (continuous variables). Models were fitted independently by dependent variable (Glyco Hb and FIB-4) and assumed a Gaussian distribution for the residuals. Some variables were removed from the final model to avoid multi-collinearity: firstly, BMI and BSA which are intimately correlated and thus, BMI was the only one included; secondly, E, Lateral e’ and E/e’ are functionally related to each other and thus only E/e’ was included in the model; lastly, LAVI and LADI. Only LAVI was included in the model since it is the strongest method to predict any and moderate to severe diastolic dysfunction.

All modeling was performed using PROC GAM in SAS/STAT v.9.4. Modeling effects are displayed as risk ratios with their 95% confidence intervals. Non-linear associations of continuous variables evaluated as smoothing splines are evaluated through an analysis of deviance using a cubic pattern (3 degrees of freedom). Smoothing component plots included a 95% curve-wise Bayesian confidence band for each component. Two-tailed \( P \)-values $<0.05$ were considered statistically significant.

RESULTS
In total, 102 patients were retrospectively identified who met inclusion and exclusion criteria. Their descriptive characteristics including mean, standard deviation, and range of values are shown in Table 1 for continuous variables and frequency and percentage proportion are shown in Table 2 for categorical variables. Patients with a left ventricular ejection fraction less than 50% were excluded.

Parameter estimates obtained through GAMs displayed as risk ratio significant association ($p < 0.05$) between glyco Hb with BMI ($P = 0.0043$) and E/e’ ($P = 0.0345$).
Table 1  Descriptive statistics continuous parameters evaluated in the study cohort.

| VARIABLE       | MEAN  | STD DEV | RANGE |
|----------------|-------|---------|-------|
| Age (yrs)      | 69.245| 12.916  | 31    | 94   |
| BMI (kg/m2)    | 30.559| 9.055   | 14.8  | 55   |
| BSA (m2)       | 1.941 | 0.334   | 1.28  | 2.85 |
| Glyco%         | 6.850 | 1.879   | 4.7   | 14   |
| BNP (pg/ml)    | 2487.9| 4733.9  | 6     | 35000|
| FIB-4          | 2.427 | 2.773   | 0.26  | 21.47|
| LAVI (ml/m2)   | 34.176| 12.372  | 11    | 69   |
| LADI (cm/m2)   | 2.077 | 0.473   | 1.2   | 4.1  |
| E (m/sec)      | 1.005 | 0.346   | 0.088 | 2.074|
| Lat e' (m/sec)| 0.107 | 0.161   | 0.035 | 1.23 |
| E/e'           | 13.936| 6.041   | 4     | 34   |

Table 2  Descriptive statistics of categorical parameters evaluated in the study cohort.

| VARIABLE       | FREQUENCY | % |
|----------------|-----------|---|
| Gender         |           |   |
| Female         | 58        | 56.9|
| Male           | 44        | 43.1|
| CADrwma        |           |   |
| No             | 76        | 74.5|
| Yes            | 26        | 25.5|
| Valve Disease  |           |   |
| No             | 95        | 93.1|
| Yes            | 7         | 6.9 |
| HTN            |           |   |
| No             | 23        | 22.5|
| Yes            | 79        | 77.5|

Notes.
CADrwma, CAD regional wall motion abnormalities.

Figure 1. Risk ratio parameter estimates of Glyco% and FIB-4 models. Sex (M/F) and comorbidities (Yes/No) were defined as parametric responses while age, BMI, BNP, LAVI and E/e’ were defined as spline smoothing components. Significantly associated effects ($P < 0.05$) are marked by an asterisk (*).

For both models, glyco Hb and FIB-4, neither sex nor comorbidity confounders of CAD, valve disease, and HTN were significantly associated (Figure 1). No significant associations to FIB-4 in general were detected in this model mode. However, spline smoothing components for linearly defined effects are presented in Figure 2 where only one significant spline smoothing component was detected for BNP ($P = 0.0019$, through
analysis of deviance) in the FIB-4 model. Although it remained non-significant for FIB-4 prediction ($P = 0.2043$).

Subsequent model iterations, where parameter estimates were differentiated based on glyco Hb grouping (the “low group” being defined as having glyco Hb 6.5 or less while the “high group” being defined as having glyco Hb over 6.5), detected only an increased risk associated to age for the low group when estimating glyco Hb. This data is presented in Table 3. In these models, neither sex nor comorbidity associations to glyco Hb or FIB-4 were detected. In summary, some predictive potential for BMI and $E/e'$ was observed for glyco Hb models adjusted for comorbidities, although no comorbidities were associated.

For low group vs high group models, only age was detected as significantly predictive. No predictive potential was detected in general for FIB-4 criteria in the main model and in the subsequent low group vs high group model iteration.

**DISCUSSION**

Advanced glycation end product (AGE) formation is characterized by the glycation of plasma proteins during longstanding hyperglycemia. These AGE’s then stimulate transmembrane receptors of advance glycation end products (rAGE) on somatic cells including cardiac myocytes resulting in alteration of intracellular signaling, gene expression, release of pro-inflammatory molecules and free radicals. These processes, at least in part, are thought to play a role in the development of cardiac fibrosis independent of the classic vascular complications related to diabetes mellitus.

In contrast to transmembrane rAGE, soluble receptors for advance glycation end products (sRAGE) function to reduce risk associated with transmembrane rAGE by the pre-transmembrane binding of AGEs and subsequent reduction of intracellular rAGE signaling. Specific sRAGEs have been identified and may have the potential to serve as markers for AGE-related cardiac risk.

As an early glycation end product, glyco Hb is nicely positioned as a hemodynamic risk marker inside this mechanism. Additionally, as lipids are thought to play a role in hepatic steatosis and liver fibrosis as well as in cross linking to form more advanced glycation end products capable of stimulating transmembrane rAGE, easily obtainable markers for liver fibrosis could serve as markers for cardiac fibrosis, which is what prompted the evaluation of FIB-4 in this study.
Stage A heart failure patients are an attractive cohort to study, in that early intervention may provide significant attenuation of disease in this patient population. The definition of stage A heart failure in this study was applied to a cohort primarily defined by normal LV systolic function. In controlling for patients with underlying hypertension, CAD, and valvular heart disease we further isolated the cohort to a stage A definition. The difficulty was in using diastolic dysfunction as an independent variable which could be seen as excluding our cohort from true stage A characteristics.

Given that the degree of diastolic dysfunction based on E/A changes needed to advance patients from the stage A category is not clear in the definition of stage A heart failure, we tried to utilize the more sensitive “pre-clinical” markers for left atrial pressure and chronic diastolic dysfunction: LAVI and E/e’.

The use of the dependent variables glyco Hb and FIB-4 was designed to capture simple and easily obtainable markers for cardiac fibrosis. In that current diabetes guidelines recommend a goal for hypoglycemic therapy to a glyco Hb of less than 7.5, defining the study group as those who meet a definition for DM but may not yet require hypoglycemic therapy makes the results more applicable for cardiac risk reduction, as opposed to simple glycemic control.

FIB-4, used as a marker for liver fibrosis which is often associated with hyperglycemia and hyperlipidemia and of the same potential mechanism as metabolic cardiac fibrosis was attractive in that age as detected in our low group model iteration, platelets, AST and ALT are its formulaic components, however we did not find an association between FIB-4 and measures of diastolic dysfunction. Additionally, the lack of a clear correlation

### Table 3 Low group vs high group parameter estimates.

“Low group” being defined as having Glyco% 6.5 or less while the “high group” being defined as having Glyco% over 6.5. Groupings were evaluated independently for each Glyco% and FIB-4. Sex (M/F) and comorbidities (Yes/No) were defined as parametric responses while age, BMI,BNP, LAVI and E/e’ were defined as spline smoothing components. Significantly associated effects (P < 0.05) are marked by an asterisk (*).

| Parameter       | Low Group Glyco% (6.5% or less) | High Group Glyco% (6.5% or more) |
|-----------------|---------------------------------|----------------------------------|
|                 | Estimate | Standard Error | P      | Estimate | Standard Error | P      |
| **Glyco%**      |          |                |        |          |                |        |
| Gender: F       | -0.019   | 0.123          | 0.8782 | 0.720    | 0.688          | 0.3074 |
| CADrmwa: No     | 0.003    | 0.125          | 0.9811 | 0.980    | 0.847          | 0.2600 |
| Valve disease: No | 0.264    | 0.183          | 0.1581 | -0.595   | 1.582          | 0.7107 |
| HTN: No         | 0.153    | 0.136          | 0.2667 | -0.810   | 0.947          | 0.4023 |
| Linear (Age)    | 0.009    | 0.005          | 0.0472*| -0.023   | 0.029          | 0.4366 |
| Linear (BMI)    | 0.014    | 0.008          | 0.0865 | -0.044   | 0.04           | 0.2781 |
| Linear (BNP)    | 1.90E+05 | 9.70E-06       | 0.0621 | 1.10E+04 | 1.20E+04       | 0.3634 |
| Linear (LAVI)   | -0.004   | 0.005          | 0.4711 | -0.015   | 0.028          | 0.5918 |
| Linear (E/e’)   | 0.008    | 0.012          | 0.4953 | 0.090    | 0.057          | 0.1264 |
| **Fib4**        |          |                |        |          |                |        |
| Gender: F       | 0.790    | 0.915          | 0.3947 | -0.547   | 0.598          | 0.3710 |
| CADrmwa: No     | 0.934    | 0.923          | 0.3196 | -0.775   | 0.736          | 0.3039 |
| Valve disease: No | 0.973    | 1.354          | 0.4776 | 2.077    | 1.374          | 0.1456 |
| HTN: No         | 0.801    | 1.005          | 0.4317 | -1.596   | 0.823          | 0.0660 |
| Linear (Age)    | -0.020   | 0.033          | 0.5518 | -0.015   | 0.025          | 0.5597 |
| Linear (BMI)    | 0.051    | 0.057          | 0.3772 | 0.011    | 0.035          | 0.7615 |
| Linear (BNP)    | 6.00E-05 | 7.20E-05       | 0.4089 | 5.80E-05 | 1.10E-04       | 0.5952 |
| Linear (LAVI)   | 0.019    | 0.039          | 0.6280 | -0.022   | 0.025          | 0.3854 |
| Linear (E/e’)   | -0.066   | 0.088          | 0.4575 | -0.014   | 0.049          | 0.7858 |

Notes.

CADrmwa, CAD regional wall motion abnormalities.
between cardiac fibrosis markers and BNP is notable given that there is evidence that higher levels of BNP are related to progressive diastolic cardiac dysfunction. This lack of correlation may be explained and/or mitigated by the study design involving only stage A (generally minimally symptomatic or asymptomatic) and not progressive stages of heart failure.

Two measures of diastolic function were used to assess the AGE-myocardial hypertrophy hypothesis. Left atrial volume was seen as reflective of “the cumulative chronic effect of LV filling pressure over time”. The E/e’ ratio was also used as a doppler measure of diastolic function because it combines the ratio of a transmitral flow measurement (a marker for the transmitral pressure gradient) with a tissue Doppler measurement (a marker of LV diastolic pressure) which is more sensitive for diastolic dysfunction.

Distinguishing glyco Hb as a compliance marker for progressive cardiac diastolic dysfunction beyond a non-specific vascular risk marker has been demonstrated. This distinction is what sets diabetic cardiomyopathy apart from standard diabetic vascular risk factors and raises the specter of earlier hemodynamic primary preventative cardiac therapy even earlier than standard glycemic goals may dictate, especially in light of SGLT2 inhibitor effects.

CONCLUSION

In patients with clinical cardiovascular risk characterized as stage A heart failure, glyco Hb may be useful as a sensitive marker to identify those most at risk for disease progression based on diastolic hemodynamic parameters. Additionally, glyco Hb may identify target patients for whom a preventative cardiovascular treatment regimen, via the cardioprotective effects of newer glycemic agents, may be beneficial even prior to a glycemic indication for therapy.

REFERENCES

[1] Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2011;29(3). doi: 10.2337/diacin.29.3.116.
[2] The UK Prospective Diabetes Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837–853.
[3] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329(14). doi: 10.1056/NEJM199309303291401.
[4] Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002;287(19). doi: 10.1001/jama.287.19.2570.
[5] Fox CS. Trends in cardiovascular complications of diabetes. JAMA. 2004;292(20). doi: 10.1001/jama.292.20.2495.
[6] vanHeerebeek L, Hamdani N, Handoko ML, Falco-Pires I, Kupriashvili K, MustersRene. Diastolic Stiffness of the Failing Diabetic Heart. Circulation. 2008;117(1): doi: 10.1161/CIRCULATIONAHA.107.728550.
[7] Levelt E, Gulsin G, Neubauer S, McCann GP. Mechanisms in endocrinology: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology. 2018;178(4). doi: 10.1530/EJE-17-0724.
[8] Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. The Korean Journal of Physiology & Pharmacology. 2014;18(1). doi: 10.4196/kjpp.2014.18.1.1.
[9] Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nature Reviews Endocrinology. 2016;12(3). doi: 10.1038/nrendo.2015.216.
[10] Hunt SA, Abraham WT, Chin MH, Feldman A, Francis G, Ganiats T. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article. Circulation. 2005;112(12). doi: 10.1161/CIRCULATIONAHA.105.167587.
[11] Ammar KA, Jacobsen SJ, Mahoney DW, Kors J, Redfield M, Burnett J. Prevalence and prognostic significance of heart failure stages. Circulation. 2007;115(12). doi: 10.1161/CIRCULATIONAHA.106.666818.
[12] Mahaffey KW, Jardine MJ, Bompoint S, Cannon C, Neal B, Heerspink H. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9). doi: 10.1161/CIRCULATIONAHA.119.042007.
[13] Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. Journal of the American Heart Association. 2019;8(20). doi: 10.1161/JAHA.119.013389.

[14] From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction. Journal of the American College of Cardiology. 2010;55(4). doi: 10.1016/j.jacc.2009.12.003.

[15] Older adults: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(1). doi: 10.2337/dc19-S012.

[16] Lang RM, Bierig M, Devereux RB, Flachskampf F, Foster E, Pellikka P. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. Journal of the American Society of Echocardiography. 2005;18(12). doi: 10.1016/j.echo.2005.10.005.

[17] Verbraecken J, van de Heyning P, de Backer W, van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55(4). doi: 10.1016/j.metabol.2005.11.004.

[18] Stefano GT, Zhao H, Schluchter M, Hoit BD. Assessment of echocardiographic left atrial size: accuracy of M-mode and two-dimensional methods and prediction of diastolic dysfunction. Echocardiography. 2012;29(4). doi: 10.1111/j.1540-8175.2011.01643.x.

[19] Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. The Korean Journal of Physiology & Pharmacology. 2014;18(1). doi: 10.4196/kjpp.2014.18.1.1.

[20] Dozio E, Vianello E, Bandera F, Longhi E, Brizzola S, Nebuloni M. Soluble receptor for advanced glycation end products: a protective molecule against intramyocardial lipid accumulation in obese Zucker rats? Mediators of Inflammation. 2019;2019. doi: 10.1155/2019/2712376.

[21] Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology. 2018;15(7). doi: 10.1038/s41575-018-0010-0.

[22] Ammar KA, Jacobsen SJ, Mahoney DW, Kors J, Redfield M, Burnett J. Prevalence and prognostic significance of heart failure stages. Circulation. 2007;115(12). doi: 10.1161/CIRCULATIONAHA.106.666818.

[23] Andersen OS, Smiseth OA, Dokainish H, Abudiab M, Schutt R, Kumar A. Estimating left ventricular filling pressure by echocardiography. Journal of the American College of Cardiology. 2017;69(15). doi: 10.1016/j.jacc.2017.01.058.

[24] Mitter SS, Shah SJ, Thomas JD. A test in context. Journal of the American College of Cardiology. 2017;69(11). doi: 10.1016/j.jacc.2016.12.037.

[25] Eroglu S, Bozbas H, Muderrisoglu H. Diagnostic value of BNP in heart failure. Biochemia Media. 2008;18(2). doi: 10.11613/BM.2008.018.